Articles published by Cofactor Genomics, Inc.

Cofactor Genomics Publishes Analytical Validation of OncoPrism-HNSCC, Highlighting Robustness of The AI-powered RNA Test In Predicting Cancer Patient Response To Immunotherapy

February 12, 2025

From Cofactor Genomics, Inc.

Via Business Wire

Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test

January 08, 2025

From Cofactor Genomics, Inc.

Via Business Wire

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer Patients

November 15, 2024

From Cofactor Genomics, Inc.

Via Business Wire

Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy

November 07, 2024

From Cofactor Genomics, Inc.

Via Business Wire

Precision Medicine Global Thought Leader, Dr. Howard McLeod, Joins Cofactor Genomics’ Advisory Board as Cofactor Brings OncoPrism test to Partnered Hospitals

October 29, 2024

From Cofactor Genomics, Inc.

Via Business Wire

Cofactor Genomics receives Medicare coverage for OncoPrism®, a machine learning-based RNA oncology test predicting immunotherapy response

October 18, 2024

From Cofactor Genomics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.